UK's No-Deal Brexit Plans Revealed For Pharma Sector

The UK government has published “technical notices” explaining what would change in the drug regulatory arena in the event of a no-deal Brexit, and what stakeholders need to do to prepare. Companies will be expected to stockpile medicines in the immediate run-up to the UK's departure from the EU.

Maze
UK government is trying to negotiate the "no-deal Brexit" maze

In the "unlikely" event of a no-deal Brexit where the current regulatory arrangements between the UK and the EU would fall away, the UK government says it would unilaterally accept batch testing of approved and investigational medicines carried out in EU countries. In the meantime, life science companies have been asked to stockpile an additional six weeks' supply of medicines in the run up to the UK's departure from the EU at the end of March 2019 - "a massive challenge", according to one trade group.

The UK regulator, the MHRA, would assume the regulatory functions currently undertaken by the EU in areas such as new...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe